|
Pentixapharm Holding AG / Key word(s): Preliminary Results Pentixapharm Holding AG Closes the 2024 Financial Year With a Loss of EUR 14 Million, Including Risk Provisions for Myelo Amounting to EUR 7 Million 24-Jan-2025 / 17:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group. The issuer is solely responsible for the content of this announcement. Berlin, January 24, 2025 – According to initial preliminary evaluations, Pentixapharm Holding AG will close the 2024 financial year with a loss of around EUR 14 million. In addition to the operating loss of EUR 7 million, the total also includes non-cash write-downs for intangible assets. They result from the termination of development projects at the subsidiary Myelo Therapeutics GmbH, which were previously mainly financed by contracts from various US government agencies. According to the opinion of the Management Board and Supervisory Board, the recent change in the U.S. administration has significantly worsened the conditions for amortization, as previous funding programs have been canceled or not extended. The annual report for 2024 with details of the development project will be published on April 15, 2025. For more information, please contact: Pentixapharm Holding AG End of Inside Information Information and Explanation of the Issuer to this announcement: About Pentixapharm Pentixapharm is a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals with offices in Berlin and Würzburg, Germany. It is committed to developing ligand-based first-in-class radiopharmaceutical approaches with a clear commercial pathway for diagnostic and therapeutic programs. Its pipeline features CXCR4-targeted compounds as well as early-stage radionuclide-antibody conjugates addressing hematological and solid cancers, as well as cardiovascular, endocrine, and inflammatory diseases. 24-Jan-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
BioArctic AB and Eisai’s Leqembi receives approval in China
Share this article Lecanemab treats MCI due to Alzheimer’s disease and mild AD dementia. Credit: CGN089 / Shutterstock.com. BioArctic AB and its partner Eisai have
January 10, 2024